Covalon Responds to FDA's Request for Further Information

April 04, 2005

MISSISSAUGA, ONTARIO--(CCNMatthews - April 4, 2005) - Covalon
Technologies Ltd. (TSX VENTURE:COV) is extremely pleased to announce
that it has responded to the FDA's request for further information
regarding the company's 510(K) Pre-Market Notification for its
ColActive(TM) wound dressing.

ColActive(TM) is a novel, proprietary collagen wound dressing developed
by Covalon which will be marketed by Hartmann-Conco Inc. through an
exclusive distribution agreement for the United States. The collagen
wound dressing category is an important in one in the United States and
Medicare/Medicaid reimbursement is significant. Since there are few
suppliers of collagen dressings Covalon and Hartmann expect to have
significant impact in this market.

The Hartmann-Conco group comprises of several wholly-owned subsidiaries
in 36 countries and other joint venture operations. It is one of the
leading companies in its branch of industry with a sales revenue of EURO
1.3 billion in 2003 and employing 10,000 people. Hartmann-Conco is a
world-class manufacturer of wound-dressings and other surgical and
hygiene products. Hartmann-Conco is owned by Paul Hartmann AG, a major
global manufacturer of wound care products, with its head office located
in Heidenheim Germany.

Covalon Technologies Ltd. is an advanced medical biosystems company that
has developed and patented advanced therapeutic biomaterials for wound
care and surgical applications as well as coatings. Polymer chemistry
and surface coating technology have been combined to create a range of
time-release drug delivery platforms that are applied to many medical
devices to treat many critical conditions. A variety of applications for
these technologies have been identified and specific products have been
developed. The products offer features and benefits providing solutions
to many of the problems caused by current devices and their material
properties, which are used by most medical device manufacturers and
suppliers. The problems include infection, poor biocompatibility, and
microbial attachment.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. The TSX
Venture Exchange has in no way passed upon the merits of the proposed
transaction and has neither approved nor disapproved of the contents of
this release.

This document contains forward-looking statements. These statements
relate to future events or future performance. In some cases,
forward-looking statements can be identified by terminology such as
"may", "will", "should", "expect", "plan", "anticipate", "believe",
"estimate", "predict", "potential", "continue" or the negative of any of
these terms or comparable terminology. Such statements reflect the
current views of management of the Company with respect to future
events. Actual events or results may differ materially. Given these
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. The Company disclaims any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained herein to
reflect future results, events or developments.

For further information please contact: William Jackson
Chief Financial Officer
Covalon Technologies Ltd.
T: (905) 568-8400
F: (905) 568-5200
www.covalon.com